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Background: Intraoperative in situ identification of 18F-FDG-avid tissue sites during radioguided oncologic surgery
remains a significant challenge for surgeons. The purpose of our study was to evaluate the 1.5-to-1 ratiometric
threshold criteria method versus the three-sigma statistical threshold criteria method for determination of gamma
detection probe positivity for intraoperative in situ identification of presumed abnormal 18F-FDG-avid tissue sites in
a manner that was independent of the specific type of gamma detection probe used.
Methods: From among 52 patients undergoing appropriate in situ evaluation of presumed abnormal 18F-FDG-avid
tissue sites during 18F-FDG-directed surgery using 6 available gamma detection probe systems, a total of 401
intraoperative gamma detection probe measurement sets of in situ counts per second measurements were
cumulatively taken.
Results: For the 401 intraoperative gamma detection probe measurement sets, probe positivity was successfully met by
the 1.5-to-1 ratiometric threshold criteria method in 150/401 instances (37.4%) and by the three-sigma statistical threshold
criteria method in 259/401 instances (64.6%) (P < 0.001). Likewise, the three-sigma statistical threshold criteria method
detected true positive results at target-to-background ratios much lower than the 1.5-to-1 target-to-background ratio of
the 1.5-to-1 ratiometric threshold criteria method.
Conclusions: The three-sigma statistical threshold criteria method was significantly better than the 1.5-to-1 ratiometric
threshold criteria method for determination of gamma detection probe positivity for intraoperative in situ detection of
presumed abnormal 18F-FDG-avid tissue sites during radioguided oncologic surgery. This finding may be extremely
important for reshaping the ongoing and future research and development of gamma detection probe systems that are
necessary for optimizing the in situ detection of radioisotopes of higher-energy gamma photon emissions used during
radioguided oncologic surgery.
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The use of intraoperative gamma probe detection technol-
ogy has become a mainstay in the surgical management of
many solid malignancies [1]. While current commercially-
available gamma detection probe technology works
well for detecting radioisotopes of low-energy gamma
photon emissions, such as 99mTc (140 and 142 KeV), the
detection of radioisotopes of higher-energy gamma pho-
ton emissions, such as 18F-fluorodeoxyglucose (18F-FDG),
which is based upon 511 KeV gamma emissions following
positron annihilation, remains a significant challenge
for surgeons [1,2]. With increasing experience in 18F-FDG-
directed surgery techniques [1-45], multiple investigators
have recognized the challenges related to the intraoperative
in situ identification presumed abnormal 18F-FDG-avid
tissue sites during radioguided oncologic surgery
[2,8,14,18,19,21,28,46-49].
The most significant challenge related to successful
intraoperative in situ identification of presumed abnormal
18F-FDG-avid tissue sites during 18F-FDG-directed surgery
is the particular situation of encountering a resultant low
target-to-background ratio from the radiation emissions
of 18F-FDG [2,8,14,18,19,21,28,46-49]. It has been
suggested by some authors that a minimum in situ target-
to-background ratio of 1.5-to-1 for 18F-FDG is necessary
for allowing the surgeon to comfortably differentiate
tumor-bearing tissues from that of normal tissue dur-
ing 18F-FDG-directed surgery [14,18,19]. However, this
target-to-background ratio represents an arbitrary and
fixed ratio determination that can be affected by multiple
factors, including 18F-FDG uptake by tumor-bearing
tissues, the distribution and degree of background
radiation within various surrounding tissues which do not
represent tumor-bearing tissues, and innumerable factors
related to the technical specifications of the specific
detection probe system used for making counts per
second measurements. Our own experience with 18F-FDG-
directed surgery [1-5,20,22-27,29,31,41] has shown us that
the observed in situ target-to-background ratio of
presumed abnormal 18F-FDG-avid tissue is commonly less
than 1.5-to-1, and as previously stated is highly dependent
upon the specific detection probe system [2]. As a result,
when intraoperative detection of in situ 18F-FDG-avid
tissue sites relies solely on a fixed target-to-background
ratio (i.e., ratiometric threshold method) as the threshold
for probe positivity, the success of such detection methods
can be limited and resultantly frustrating for the surgeon
[2]. Therefore, we have suggested that improved intra-
operative in situ identification of 18F-FDG-avid tissue
sites can be accomplished by the use of the three-sigma
statistical threshold criteria method for determination of
gamma detection probe positivity [2].
The three-sigma statistical threshold criteria for deter-
mination of gamma detection probe positivity has beenpreviously well characterized by Thurston [2,50-53], and
has been previously well-utilized for radioimmunoguided
surgery involving 125I-labeled anti-TAG-72 monoclonal
antibodies [2,50-58]. The three-sigma statistical threshold
criteria defines any given tissue as being probe positive
when the count rate in that tissue exceeds three standard
deviations above the mean count rate detected within
normal adjacent tissue [2,50-58].
To further investigate our contention that improved
intraoperative in situ identification of 18F-FDG-avid
tissue sites can be accomplished by the use of the
three-sigma statistical threshold criteria method for
determination of gamma detection probe positivity,
we recently evaluated the success rate of intraoperative in
situ detection of presumed abnormal 18F-FDG-avid tissue
sites using the 1.5-to-1 ratiometric threshold criteria
method and the three-sigma statistical threshold criteria
method for three different gamma detection probe
systems in a limited data set [2]. This limited data set
consisted of a group of seven patients, representing a
total of nine separate 18F-FDG-avid tissue sites, in
which all 18F-FDG-avid tissue sites were identified by
same-day preoperative diagnostic positron emission
tomography/computed tomography (PET/CT) imaging,
were intraoperatively assessed in situ with all three gamma
detection probe systems, and were subsequently surgically
excised. In this analysis, we found that successful intraop-
erative in situ detection of 18F-FDG-avid tissue sites was
more frequently accomplished by using the three-sigma
statistical threshold criteria method than by using the
1.5-to-1 ratiometric threshold criteria method with
each of the three gamma detection probe systems
tested. Nevertheless, due to the small sample size of
our limited data set that was available for the 2 × 3
contingency table analysis, there was no significant
difference in our statistical analysis of overall comparison
of the three gamma detection probe systems utilized as a
function of the specific threshold criteria method for the
determination of gamma detection probe positivity [2].
In the current analysis, and in order to rectify the
above problem faced in our previous report regarding
limited sample size availability for statistical analysis [2],
we purposefully chose to examine the effects of utilizing
the 1.5-to-1 ratiometric threshold criteria method versus
the three-sigma statistical threshold criteria method
for determination of gamma detection probe positivity
for intraoperative in situ identification of presumed
abnormal 18F-FDG-avid tissue sites within our entire study
population in a manner that was completely independent
of the specific type of gamma detection probe system used.
As a result, this particular approach allowed for a much
larger number of intraoperative gamma detection probe
measurement sets that were available for the statistical
analysis.
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Logistics for deriving the complete data set from individual
intraoperative gamma detection probe measurement sets
of in situ counts
The data analyzed herein were obtained from the master
database of a Cancer IRB-approved, prospective, pilot
study protocol (approved by The Ohio State University
Cancer IRB) involving patients undergoing 18F-FDG-directed
surgery for known or suspected malignancy at the Arthur
G. James Cancer Hospital and Richard J. Solove Research
Institute of The Ohio State University Wexner Medical
Center. Sixty-five patients originally gave informed consent
to participate in the Cancer IRB-approved, prospective,
pilot study protocol, of which 60 patients were taken
to the operating room, of which 58 patients underwent
18F-FDG-directed surgery using available gamma detection
probes, and of which 52 patients underwent appropriate in
situ evaluation of presumed abnormal 18F-FDG-avid tissue
sites (i.e., measurements taken before any such tissue
was surgically excised) using various combinations of
6 different available gamma detection probe systems. Thus,
6 of the 58 patients who underwent 18F-FDG-directed
surgery using available gamma detection probes did
not have in situ evaluation of presumed abnormal
18F-FDG-avid tissue sites, and those 6 patients only
underwent ex situ evaluation of presumed abnormal
18F-FDG-avid tissue sites (i.e., measurements taken after
any such tissue was surgically excised). Additionally, none
of the in situ gamma detection probe measurement sets in
the 52 patients undergoing appropriate in situ evaluation
of presumed abnormal 18F-FDG-avid tissue sites using
various combinations of 6 different available gamma
detection probe systems were excluded from the analysis.
Ninety-seven separate sites were selected based on
identification of finite areas of presumed abnormal 18F-FDG-
avidity seen on a preoperative diagnostic 18F-FDG PET/CT
scan from the 52 patients described who eventually
underwent appropriate in situ evaluation of presumed
abnormal 18F-FDG-avid tissue sites. All presumed abnormal
18F-FDG-avid tissue sites were defined as abnormal as
based upon the reading and official radiology report issued
on the preoperative diagnostic 18F-FDG PET/CT scan by
the reporting attending nuclear medicine physician and
were not defined as abnormal as based upon any specific
predetermined cut-off level for the standardized uptake
value (SUV) seen in those 18F-FDG-avid tissue sites. Intra-
operatively, these 97 in situ presumed abnormal 18F-FDG-
avid sites were evaluated with various combinations of 6
available gamma detection probe systems in these 52
patients. As a result, 401 intraoperative gamma detection
probe measurement sets of in situ counts per second
measurements were cumulatively taken from among the 6
available gamma detection probe systems, representing the
complete data set used in our current statistical analyses.These 6 available gamma detection probe systems
included 4 commercially-available gamma detection probe
systems and 2 prototype experimental probe designs. The
4 commercially-available gamma detection probe systems
consisted of 2 commercially-available gamma detection
probe systems which were originally designed to detect
lower energy gamma-emitting radioisotopes (Neoprobe®
1000 and Neoprobe® 2000, formally Neoprobe Corporation,
Dublin; Ohio) and 2 commercially-available gamma
detection probe systems which were specifically designed
in an attempt to detect 511 KeV high-energy gamma
emissions from 18F-FDG positron annihilations (Neoprobe®
High Energy Probe, formally Neoprobe Corporation, Dublin;
Ohio; and RMD Navigator GPS™ Gamma-PET™ Probe,
formally RMD Instruments, Watertown, Massachusetts).
The 2 prototype experimental probe designs consisted of: (1)
a modified version of a lower energy gamma-emitting
radioisotopes-detecting commercially-available probe,
retro-fitted with a tungsten collimator of sufficient thickness
to block 90% of 511 KeV gamma radiation, and which was
intended to limit the field-of-view of the detection probe in
order to increase the target-to-background ratio; and (2) an
experimental detection probe which incorporated an x-ray
fluorescence element to transfer the 511 KeV high-energy
gamma radiation to the K-alpha x-ray energy of the element
(i.e., 72 KeV), which allowed for this lower K-alpha x-ray
energy to be counted at a higher efficiency than the 511
KeV high-energy gamma emissions [2,59].
The entire group of 401 intraoperative gamma detection
probe measurement sets of in situ counts per second
measurements collected from our entire study population
were cumulatively analyzed in a manner that was com-
pletely independent of the specific type of gamma detection
probe system used to evaluate gamma detection probe posi-
tivity for intraoperative in situ identification of presumed
abnormal 18F-FDG-avid tissue sites by the 1.5-to-1 ratio-
metric threshold criteria method and by the three-sigma
statistical threshold criteria method.
Definition of each intraoperative gamma detection probe
measurement sets of in situ counts
As previously reported [2], for each intraoperative gamma
detection probe measurement set, an averaged count rate
(i.e., counts per second) was taken from an area selected for
the in situ measurement of background tissue count rate,
and from the area of presumed abnormal 18F-FDG-avid
tissue selected for the in situ measurement of target tissue
count rate. An area of presumed normal tissue within a
region adjacent to the area of the target tissue was selected
for the measurement of background tissue count rate.
Three separate recorded values were used to generate each
averaged target tissue count rate measurement determined
for each area of presumed abnormal 18F-FDG-avid tissue.
All values used for the averaged count rate measurements
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second. Count rate normalization consists of dividing
acquired counts by the count duration in seconds. It is
important to emphasize that all of the averaged target
tissue count rate measurements that were reported in this
paper represented measurements taken on an area of
presumed abnormal 18F-FDG-avid tissue before any such
tissue was surgically excised (i.e., in situ measurements).
None of the averaged target tissue count rate measure-
ments that were reported in this paper represented
measurements taken on an area of presumed abnormal
18F-FDG-avid tissue after any such tissue was surgically
excised (i.e., ex situ measurements).
Rationale for recording in situ target tissue count rate
measurements for the intraoperative identification of
presumed abnormal 18F-FDG-avid tissue sites
A major inherent limitation in performing PET/CT
oncologic imaging with 18F-FDG is related to the fact
that 18F-FDG is not a cancer-specific imaging agent, and
for which 18F-FDG readily accumulates within tissues
representing benign disease processes (i.e., infection,
inflammation, and trauma) and 18F-FDG readily accumu-
lates within various normal tissues (i.e., brain, heart,
mucosa and smooth muscle of the stomach, small
intestines and colon, thyroid, liver, spleen, kidneys,
ureters, and bladder) that have a typical physiologic
propensity for 18F-FDG accumulation [1,2]. These sites of
benign disease accumulation and physiologic accumulation
of 18F-FDG can result in an intrinsically high level of
background 18F-FDG activity within regions of presumed
normal tissues that may co-exist with presumed abnormal
18F-FDG-avid tissue sites. This can be particularly
challenging when any given presumed abnormal 18F-FDG-
avid tissue site has a relatively low target site count rate.
Resultantly, recording the in situ measurements for the
averaged target tissue count rate on any given area of
presumed abnormal 18F-FDG-avid tissue before any such
tissue was surgically excised would represent the worst-case
scenario as related to the intrinsic background activity of
18F-FDG. Conversely, recording the ex situ measurements
for the averaged target tissue count rate on any given area
of presumed abnormal 18F-FDG-avid tissue after any such
tissue was surgically excised would represent the best-case
scenario as related to the intrinsic background activity of
18F-FDG. Therefore, to most definitively determine whether
there was any significant difference between these two
threshold detection criteria methodologies (i.e., the 1.5-to-1
ratiometric threshold criteria method and the three-sigma
statistical threshold criteria method) for determination
of probe positivity during attempted identification of
presumed abnormal 18F-FDG-avid tissue sites during
radioguided oncologic surgery, we selected the worst-case
scenario as related to the intrinsic background 18F-FDGactivity and elected to record the in situ measurements for
the averaged target tissue count rate on all presumed
abnormal 18F-FDG-avid tissue site before any such
tissue sites were surgically excised, in order to maximize
the negative impact of the intrinsic background 18F-FDG
activity.
Definition and determination of the 1.5-to-1
target-to-background ratio method for probe positivity
A target-to-background ratio was calculated for each target
tissue as defined as the ratio of the averaged target tissue
count rate to the background tissue count rate. The
ratiometric threshold of 1.5-to-1 or greater was set as
the ratiometric threshold criteria for probe positivity
(i.e., 1.5-to-1 ratiometric threshold criteria method).
Definition and theoretical derivation of the three-sigma
statistical threshold criteria method of probe positivity
For each intraoperative target tissue measurement, a
three-sigma statistical threshold criteria count rate was
calculated by the methodology popularized of Thurston
[2,50-53]. The three-sigma statistical threshold criteria
was determined from an area of presumed normal back-
ground tissue by multiplying the standard deviation of
the normal background count rate in an area of pre-
sumed normal background tissue by a factor of three,
and then adding that calculated number to the mean
value of the normal background count rate. The condi-
tion for probe positivity was met if the count rate for the
target tissue (i.e., target count rate) exceeded the calcu-
lated three-sigma criteria count rate threshold.
The three-sigma statistical threshold criteria repre-
sents a specific application of binary hypothesis testing.
The theoretical deviation of the three-sigma statistical
threshold criteria as it relates to radioactivity has its ori-
gins in the classical work of Currie [60]. In the classical
application to radioactivity by Currie [60], the presence
of a radiation source is tested against the null hypothesis
that no source is present in excess of the background
radiation. The resulting threshold for the alternative
hypothesis, i.e. that there is a source present, can be
reduced to a single variable, μB, the mean value of the
background radiation count. This threshold for accepting
the alternative hypothesis H1 takes the form:




where K1 and K2 are constants. For counts rates exceed-
ing 30 per second, K1 is considered negligibly small and the
threshold for accepting the alternative hypothesis is




In the current application, the presumed 18F-FDG-avid
tissue site contains activity from both background radiation
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ship, the combined count rates must be taken into account.
Although the following derivation is applied to raw
counts, the same analysis can be applied to count rate
measurements with no loss of generality if the count rates
are calculated using equal time intervals of raw count
measurements, and provided that the raw counts are suffi-
cient to support the statistical analysis without introducing
error secondary to insufficient sample size.
Radioactive decay is a Poisson distributed discrete
random process since each event is independent of
the preceding event. If the number of counts in a
Poisson distribution exceeds approximately 30, a continu-
ous Gaussian distribution provides a close approximation
[61]. However, the value for standard deviation used in the
Gaussian approximation must be equal to the square root
of the mean value since this is a characteristic of the
original Poisson distribution. If this condition is imposed,
the two distributions can be used interchangeably and
Z-score statistics can be applied using the one-sided
Gaussian approximation. Counts are discrete values in
both the Poisson and the corresponding Gaussian
approximation.
Consider the two probability distributions of counts
illustrated in Figure 1, with one count distribution
representing the background count measurement, and
with the second count distribution representing the
target count measurement. By definition, the target count
measurement (T) is the summation of source count
measurement (S) plus the background count measurement
(B). Since the source count is the difference between
the target count and background count, the varianceFigure 1 Illustration of the probability distribution for the backgroun
target count measurement (T) represents the summation of source count me
(P) for true positive, true negative, false positive, and false negative are shown
background count.of the source count is the sum of the variances of the
target count and the background count.
σ2S ¼ σ2T þ σ2B ð3Þ
When no source activity is present, the variance for the






The Critical Limit (LC) for false positive counts is
based on the one-sided Z parameter. A value of K is
chosen for the desired percentile of statistical certainty
above the mean background count. K times the standard
deviation of the source count distribution defines the LC
at the desired percentile such that:
LC ¼ μB þ KσS ð5Þ





If the same K parameter is chosen to define an equal
percentile of false negative and false positive probabilities,
the LC will also coincide with:
LC ¼ μD− KσD ð7Þ
μD ¼ LC þ KσD ð8Þ
where μD is the desired source count corresponding to
the minimum detectable count difference.
The standard deviation for the minimum detectible
distribution, σD, can also be expressed as a function of
the standard deviation for both the background countd count measurement and the target count measurement. The
asurement (S) plus the background count measurement (B). Probabilities
for target count rates at three standard deviations above the mean
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¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃμT þ μB
p
¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃμD þ μB þ μB
p ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃμD þ 2μB
p ð9Þ
Since μD = LC + KσD, the LC as a function of the mean
background count can be substituted.






þ K ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃμD þ 2μB
p ð10Þ
This equation can be algebraically reduced to:






K2 (a Z-table value) is less than 3 for all certainty levels
less than 95.6%, and can be considered negligible for mean
background counts greater than 30. This reduces the
minimum detectable count threshold to:





Calculating the percentile for the three-sigma statistical
threshold criteria:









p ¼ 1:0607 ð14Þ
The one-sided percentile calculation for a Z-score of
1.0607 is approximately equal to 85.6% [62].
Thus, for the three-sigma statistical threshold criteria,
the probability for either a false positive or false negative
finding is approximately 14.4%. The confidence level for
probe positivity is 85.6%. Comparing the distribution of
the background count and the target count in Figure 1
illustrates the relationship between these probabilities.
The probabilities of false positive and false negative findings
are calculated as the area under the curve in the shaded
regions indicated in Figure 1.
Statistical analysis
The software program IBM SPSS® 21 for Windows®
(SPSS, Inc., Chicago, Illinois) was used for all data
analyses. All continuous variable results were expressed as
mean (±SD, range). The probe positivity comparison for
the 1.5-to-1 ratiometric threshold criteria method versus
the three-sigma statistical threshold criteria method was
made by way of a 2 × 2 contingency table analysis using
the Pearson chi-square test. The P-value for the Pearson
chi-square test comparison was reported as an exact
two-sided P-value. A P-value of 0.05 or less was considered
to be statistically significant.The drawing software program AutoCAD LT 2010
(AutoDesk, Inc., San Rafael, California) was used for the
generation of Figure 1.
The software program MATLAB R2013b version
8.2.0.701 (MathWorks, Natick, Massachusetts) was used
for the generation of Figures 2, 3, and 4.
Results and discussion
Of the 52 patients undergoing in situ evaluation of
presumed abnormal 18F-FDG-avid tissue sites using
any given gamma detection probe system at the time
of 18F-FDG-directed surgery, there were 30 Caucasian
females, 18 Caucasian males, 2 African-American female, 1
African-American male, and 1 Asian female. The mean
patient age was 58 (±10, range 37–83) years. The mean
patient body weight was 81.7 (±20.2, range 43.5-142.9)
kilograms. The mean patient same-day pre-scanning blood
sugar level of 106 (±18, range 78–157) milligrams per
deciliter. The mean 18F-FDG injection dose was 537
(±55, range 387–611) megabecquerels. The mean time
from 18F-FDG injection to the time of the start of surgery
was 242 (±82, range 108–449) minutes. The mean time
from 18F-FDG injection to the time of the start of appropri-
ate in situ evaluation of presumed abnormal 18F-FDG-avid
tissue sites using any of the given gamma detection probe
system was 278 (±88, range 145–501) minutes.
The mean of the averaged target tissue count rate for
the 401 gamma detection probe measurement sets was
2,047 (±3,706, range 6–16,353) counts per second. The
mean of the background tissue count rate in an area of
presumed normal tissue within a region adjacent to the
presumed 18F-FDG-avid tissue site for the 401 gamma
detection probe measurement sets was 1,709 (±3,172,
range 4–13,020) counts per second. The mean of the
calculated 1.5-to-1 target-to-background ratio for the
401 gamma detection probe measurement sets was 1.53
(±0.93, range 0.12-9.88). The mean of the calculated
three-sigma statistical threshold criteria count rate for
the 401 gamma detection probe measurement sets was
1,796 (±3,257, range 11–13,362) counts per second.
For the 401 gamma detection probe measurement sets,
probe positivity was successfully met by the 1.5-to-1 ratio-
metric threshold criteria method in 150/401 instances
(37.4%) and by the three-sigma statistical threshold criteria
method in 259/401 instances (64.6%) (P < 0.001).
Our current statistical analysis, which intentionally
utilized a very large number of individual gamma
detection probe measurement sets (n = 401) of presumed
abnormal 18F-FDG-avid tissue sites that were evaluated
completely independent of the count rate determinations
by any specific type of gamma detection probe system,
clearly demonstrates that the three-sigma statistical
threshold criteria method was significantly better than
the 1.5-to-1 ratiometric threshold criteria method for
Figure 3 The receiver operating characteristic (ROC) curve for various statistical threshold criteria values for probe positivity from the
entire group of 401 gamma detection probe measurement sets is illustrated. The data curve is labeled with the specific numbers of standard
deviations indicated. The dashed line indicates a hypothesis test of no diagnostic discrimination. The ROC curve ranges from −46 to 74 standard
deviations above the mean background count rate. The operating point on the data curve for three standard deviations above the mean background
count rate is indicated as three-sigma threshold criteria (*), and corresponds to a true positive rate of 71% and false positive rate of 40%. Two-sigma
operating point is indicated by (●). The optimal operating point is indicated by (+). The area under the ROC curve is 0.6728 (67.3%).
Figure 2 Plot of the target-to-background ratio and mean background count rate for those 291 of the 401 gamma detection probe
measurement data sets that were limited to a mean background count rate range of less than 1250 counts per second. Malignant 18F-FDG-
avid tissue sites are shown as (o) and benign18F-FDG-avid tissue sites are shown as (x). The thresholds for probe positivity, expressed as target-to-
background ratios, are graphed as a function of the mean background count rate. The ratiometric threshold criteria of 1.5-to-1 is shown as a dashed
line and the three-sigma threshold criteria is shown as a solid line curve.
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Figure 4 The receiver operating characteristic (ROC) curve for various ratiometric threshold criteria values for probe positivity from
the entire group of 401 gamma detection probe measurement sets is illustrated. The ROC curve ranges from target-to-background ratios
of −1-to-1 to 9-to-1 above the mean background count rate. The 1.5-to-1 ratiometric operating point is indicated by (*). The 1.33-to-1 (optimal)
ratiometric operating point is indicated by (+). The area under the ROC curve is 0.7150 (71.5%).
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intraoperative in situ identification of presumed abnormal
18F-FDG-avid tissue sites during 18F-FDG-directed surgery.
The authors fully acknowledge and accept the well-
established fact that the finding of 18F-FDG-avidity within
any given area of tissue is not an absolute indication that
one will find the presence of malignancy within that given
area of tissue. To further explore this subject matter,
subset analysis was subsequently performed, as specifically
based upon the postoperative histopathologic determin-
ation of the finding of malignant tissue versus benign
tissue from all tissue specimens comprising the entire
group of 401 gamma detection probe measurements sets
initially analyzed. Table 1 shows the arbitrary breakdown
of in situ probe positivity and in situ probe negativity
versus the postoperative histopathologic determination of
the finding of malignant tissue versus benign tissue. Of
the 401 gamma detection probe measurements sets taken
in situ from presumed abnormal 18F-FDG-avid tissueTable 1 Definitions for in situ probe positivity and in situ
probe negativity versus the postoperative histopathologic








Malignant True Positive (TP) False Negative (FN)
Benign False Positive (FP) True Negative (TN)sites, postoperative histopathologic evaluation identified
323 malignant tissue specimens and 78 benign tissue
specimens. Figure 2 shows the plot of the target-to-
background ratio and mean background count rate
for each malignant tissue site (o) and each benign tissue
site (x) for those 291 of the 401 gamma detection probe
measurement data points within the area of relevancy
(i.e. around the ratiometric threshold criteria range of
1.5-to-1 for the target-to-background ratio and within
the lower background count rate range of less than
1250 counts per second). Table 2 shows the frequency of
true positives (TP), false positives (FP), true negatives
(TN), and false negative (FN) versus threshold criteria
method. Table 2 illustrates the increase in the number of
malignant tissue sites identified as in situ probe positive
using the three-sigma statistical threshold criteria method
as compared to the 1.5-to-1 ratiometric threshold criteria
method. As evident in Figure 2, there were numerous in
situ probe positive measurement data points above the
solid line curve for the three-sigma statistical thresholdTable 2 Frequency of true positives (TP), false positives






TP FP TN FN TP FP TN FN
138 12 66 185 228 31 47 95
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criteria dashed line.
The solid line in Figure 2, representing the three-
sigma statistical threshold criteria curve, illustrates the
advantage of the three-sigma statistical threshold criteria
over that of the 1.5-to-1 ratiometric threshold criteria.
Unlike the ratiometric threshold, in theory, the three-
sigma statistical threshold approaches a 1-to-1 target-to-
background ratio as the mean background count rate
increases. For this reason, a gamma detection probe of
higher counting efficiency is capable of detecting lower
target-to-background ratios when the three-sigma statistical
threshold criteria is applied. At increased mean background
count rates, the three-sigma statistical threshold criteria
can theoretically detect target-to-background ratios as low
as 1.1-to-1 with a statistical confidence level of greater than
85.6%, as previously shown in Figure 1 (i.e., probability of
true positives) and in the derivation of three-sigma statis-
tical threshold criteria method of probe positivity in the
Methods section.
By contrast, in theory, the ratiometric threshold criteria
method for determining probe positivity will result in an
inconsistent statistical confidence level for target count
rate measurements. The statistical confidence level of tar-
get count rate measurements is reduced at lower target
count rates. As a result, the statistical confidence level for
probe positivity when applying the ratiometric threshold
criteria is an unknown variable at the time of in situ target
count rate measurement. This is not the case when using
statistical threshold criteria methods for probe positivity,
since the statistical confidence level remains constant re-
gardless of the count rate of the individual target count
rate measurements.
The sensitivity (i.e., true positive rate) and the specificity
(i.e., true negative rate) for the two threshold criteria
methods (i.e., 1.5-to-1 ratiometric threshold criteria and
three-sigma statistical threshold criteria) are shown in
Table 3, and were calculated for the entire group of 401
gamma detection probe measurement sets using the post-
operative histopathologic determination of malignant tissue
versus benign tissue from Table 1 and the frequency of true
positives (TP), false positives (FP), true negatives (TN), and
false negative (FN) versus threshold criteria method from
Table 2. The use of the three-sigma statistical threshold













0.85 0.60a 25% decrease in specificity. It is our contention that
increased sensitivity of a detection probe system generally
represents a much more influential variable for affecting
long-term patient outcome than does the loss of specificity
of a detection probe system. The advantage of the higher
sensitivity is the allowance of fewer instances in which areas
of malignant tissue will go undetected and inadvertently
unresected within any given patient. The negative impact of
a lower specificity (i.e., more false positive findings) is the
increased frequency of possible unnecessary surgical exci-
sion of areas of nonmalignant tissue in any given patient.
From a clinical perspective, inadvertently leaving unre-
sected malignant tissues within any given patient represents
a far greater risk to the patient than does surgically excising
tissues from the patient that are later found to be non-
malignant. This premise is well-supported by long-term
survival data from antigen-directed cancer surgery for
patients with primary colorectal cancer [63,64]. For this
reason, the three-sigma statistical threshold criteria method
represents a marked improvement over the 1.5-to-1 ratio-
metric threshold criteria method for the successful intra-
operative detection of malignant tissue.
In generally, the receiver operating characteristic (ROC)
is a concept used in signal detection theory to illustrate the
performance of a binary classification system as the
discrimination threshold is varied [65-67]. In the current
analysis, the ROC provides an alternative method for com-
paring true positive rate and false positive rate (1-specificity).
Each point on any given ROC curve is the true positive rate
(sensitivity) plotted against the false positive rate (1-specificity)
resulting from the threshold for probe positivity calculated
for a single value. At each new threshold for probe positiv-
ity, the sensitivity and specificity were recalculated. It is
essential to understand that the ROC curve, as well as
sensitivity and specificity, are measuring the predictive
values of not only the threshold for probe positivity, but
also the entire diagnostic system, including the specifica-
tions of the gamma detection probe system utilized, as well
as the subjective selection by the surgeon of the back-
ground site and the target tissue sites for recording each
measurement data set. Moreover, differing data sets result
in some change to the ROC curve. However, within a
single ROC curve, examining the effect of changing the
threshold on sensitivity and specificity is valid, provided
that the changes in the statistical confidence level for the
analysis is also taken into consideration.
The ROC curve for various statistical threshold criteria
values for probe positivity from the entire group of 401
gamma detection probe measurement sets is illustrated in
Figure 3. Figure 3 illustrates the ROC of the current data
set as the number of standard deviations was varied from
a value of −46 to 74 in nonlinear increments to generate a
complete curve. The ROC curve was generated by varying
the number of standard deviations that must be exceeded
Table 4 Frequency of true positives (TP), false positives
(FP), true negatives (TN), and false negative (FN) as a
function of four various probe positive threshold criteria
Threshold criteria method TP FP TN FN
3-Sigma Statistical 228 31 47 95
4.3-Sigma Statistical 211 25 53 112
1.5-to-1 Ratiometric 138 12 66 185
1.33-to-1 Ratiometric 183 17 61 140
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tive threshold. The operating point on the data curve for
three standard deviations above the mean background
count rate (i.e., three-sigma statistical threshold) indicated
by the * symbol in Figure 3, corresponds to a true positive
rate of 71% and false positive rate of 40%. Ideally, the true
positive rate of the diagnostic test would be maximized
(close to 100%) and the false positive rate would be mini-
mized (approaching 0%) [65]. The current data set
suggested that a statistical threshold using fewer than
three standard deviations above the mean background
count rate can increase the true positive rate without
exceeding a 50% false positive rate. However, this modifi-
cation would also result in a reduction in the statistical
confidence level of the measurement. A statistical thresh-
old for probe positivity of the mean background count
rate plus two standard deviations, for example, would
reduce the statistical confidence level of a true positive
and true negative measurement from a 85.6% probability
for three-sigma statistical threshold to a 76.0% probability
for the for two-sigma statistical threshold.
It is also a common practice to identify the point on the
ROC curve that represents the best combination of specifi-
city and sensitivity [67]. In Figure 3, this point occurs at the
location on the data curve that is closest to a true positive
rate of a value of one and a false positive rate of a value of
zero, which is located in the upper left hand corner of the
plot. For the current data set shown in Figure 3, the best
combination of specificity and sensitivity, as indicated by the
+ symbol, occurred at a true positive rate of 65% and false
positive rate of 32%, and corresponds to a probe positive
threshold level of the mean background count rate plus 4.3
standard deviations. Although utilizing this approach for
identifying an optimal operating point on the ROC curve is
commonplace, the resultant sensitivity of 65% for any such
diagnostic instrument which would be used for detecting
18F-FDG-avid tissue sites would be considered suboptimal
and would make any such diagnostic instrument clinically
ineffective. Therefore, it is our opinion that the three-sigma
statistical threshold criteria (i.e., probe positive threshold
level of the mean background count rate plus 3 standard
deviations) for determination of gamma detection probe
positivity represents a good balance of sensitivity, selectivity,
and statistical confidence levels for positive and negative
probabilities. This contention for our support of the three-
sigma statistical threshold criteria for determination of
gamma detection probe positivity is further borne out in
the fact that the three-sigma statistical threshold criteria is
routinely used in other medical applications and commercial
products that detect signals in the presence of background
noise, such as radar detectors [68-70].
The ROC curve for various ratiometric threshold criteria
values for probe positivity from the entire group of 401
gamma detection probe measurement sets is illustrated inFigure 4. A similar analysis can be applied to the ratio-
metric threshold for probe positivity. Figure 4 illustrates the
ROC of the current data set as the ratio for target-to-
background count rate for probe positivity is varied from
−1-to-1 to 9-to-1. The optimal operating point the ratio-
metric threshold ROC curve occurred at a target-to-
background ratio of 1.33-to-1. It should be noted that this
value validates our earlier contention that a target-to-
background ratio that is lower than 1.5-to-1 is required to
adequately detect 18FDG-avid sites which are subsequently
determined to be malignant.
In Table 4, we have summarized the frequency of true
positives (TP), false positives (FP), true negatives (TN), and
false negative (FN) as a function of four various probe
positive threshold criteria, including (1) three-sigma statis-
tical threshold (i.e., mean background count rate plus 3
standard deviations; (2) 4.3-sigma statistical threshold (i.e.,
mean background count rate plus 4.3 standard deviations;
(3) target-to-background count rate ratio of 1.5-to-1 ratio-
metric threshold; and (4) target-to-background count rate
ratio of 1.33-to-1 ratiometric threshold. The 1.33-to-1 ratio-
metric threshold represented a marked improvement over
the 1.5-to-1 ratiometric threshold as the detection of true
positives was increased from 138 to 183, and the frequency
of false negative measurements was reduced from 185 to
140. Given the impact to patient outcome, improvements
in these two parameters were more significant than the
corresponding reduction in the frequency of true negatives
and increase in the frequency of false positive measure-
ments. Neither of the ratiometric threshold criteria values
for probe positivity was as accurate in the correct detection
of true positive and false negative sites as was either of the
statistical threshold criteria values. Moreover, the three-
sigma statistical threshold criteria method provides the best
outcome for detection of both true positive and false
negative sites.
Conclusion
Our current data analysis demonstrates that the three-
sigma statistical threshold criteria method is significantly
better than the 1.5-to-1 ratiometric threshold criteria
method for determination of gamma detection probe
positivity for intraoperative in situ detection of presumed
abnormal 18F-FDG-avid tissue sites during radioguided
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threshold criteria method can detect true positive results at
target-to-background ratios that are much lower than the
1.5-to-1 target-to-background ratio of the 1.5-to-1 ratio-
metric threshold criteria method. If a surgeon utilizes a
gamma detection probe system with high count rate sensi-
tivity, it is theoretically feasible that target-to-background
ratios as low as 1.1-to-1 can be identified as in situ probe
positive 18F-FDG-avid tissue sites when applying the three-
sigma statistical threshold criteria method. This finding
may be extremely important for reshaping the ongoing and
future research and development of gamma detection
probe systems that are necessary for optimizing the in situ
detection of radioisotopes of higher-energy gamma photon
emissions used during radioguided oncologic surgery.
Competing interests
The authors declare that they have no conflict of interests specifically related
to the contents of this paper.
Authors’ contributions
GJC and SPP contributed equally to this work. GJC was involved in the study
design, data analysis and interpretation, writing of all drafts of the
manuscript, and has approved final version of the submitted manuscript.
SPP was the principle investigator for The Ohio State University Cancer
IRB-approved, prospective, pilot study protocol involving patients undergoing
18F-FDG-directed surgery for known or suspected malignancy, and was
responsible for the study design, data collection, data analysis and interpretation,
writing of all drafts of the manuscript, and has approved final version of the
submitted manuscript. NCH was involved in study design, critiquing drafts of the
manuscript, and has approved final version of the submitted manuscript. DAM
was involved in study design, data collection, data analysis, critiquing drafts of
the manuscript, and has approved final version of the submitted manuscript.
RL was involved in study design, critiquing drafts of the manuscript, and has
approved final version of the submitted manuscript. EWM was involved in study
design, critiquing drafts of the manuscript, and has approved final version of the
submitted manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank the following surgeons at The Ohio State
University Wexner Medical Center for their utilization of 18F-FDG-directed
surgery patients to this paper: Drs. Mark Bloomston, David Cohn, Amit
Agrawal, David O’Malley, Enver Ozer, Carl Schmidt, Michael Walker, Susan
Moffatt-Bruce, William Kraybill, and John Phay. The authors would like to
thank Dr. Donn Young from the Center for Biostatistics of the Comprehensive
Cancer Center at The Ohio State University Wexner Medical Center, Dr. Charles
Hitchcock from the Department of Pathology at The Ohio State University
Wexner Medical Center, and Dr. Marvin White of the Department of Electrical
and Computer Engineering at The Ohio State University. The authors would
like to thank Deborah Hurley, Marlene Wagonrod, and the entire staff of the
Division of Nuclear Medicine from the Department of Radiology at The Ohio
State University Wexner Medical Center, Nichole Storey from the Department of
Radiology at The Ohio State University Wexner Medical Center, and the entire
operating room staff from the Arthur G. James Cancer Hospital and Richard J.
Solove Research Institute at The Ohio State University Wexner Medical Center.
Author details
1Department of Electrical and Computer Engineering, The Ohio State
University, Columbus, OH 43210, USA. 2Division of Surgical Oncology,
Department of Surgery, Arthur G. James Cancer Hospital and Richard J.
Solove Research Institute and Comprehensive Cancer Center, The Ohio State
University Wexner Medical Center, Columbus, OH 43210, USA. 3Division of
Molecular Imaging and Nuclear Medicine, Department of Radiology, The
Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Received: 7 July 2014 Accepted: 10 September 2014
Published: 13 September 2014References
1. Povoski SP, Neff RL, Mojzisik CM, O’Malley DM, Hinkle GH, Hall NC, Murrey DA Jr,
Knopp MV, Martin EW Jr: A comprehensive overview of radioguided surgery
using gamma detection probe technology. World J Surg Oncol 2009, 7:11.
2. Povoski SP, Chapman GJ, Murrey DA Jr, Lee R, Martin EW Jr, Hall NC:
Intraoperative detection of 18F-FDG-avid tissue sites using the increased
probe counting efficiency of the K-alpha probe design and variance-based
statistical analysis with the three-sigma criteria. BMC Cancer 2013, 13:98.
3. Desai D, Arnold M, Saha S, Hinkle G, Soble D, Frye J, DePalatis L, Mantil J,
Satter M, Martin E: Intraoperative gamma detection of FDG distribution in
colorectal cancer. Clin Positron Imaging 1999, 2:325.
4. Desai DC, Arnold M, Saha S, Hinkle G, Soble D, Fry J, DePalatis LR, Mantil J,
Satter M, Martin EW: Correlative whole-body FDG-PET and intraoperative
gamma detection of FDG distribution in colorectal cancer. Clin Positron
Imaging 2000, 3:189–196.
5. Zervos EE, Desai DC, DePalatis LR, Soble D, Martin EW: 18F-labeled
fluorodeoxyglucose positron emission tomography-guided surgery for
recurrent colorectal cancer: a feasibility study. J Surg Res 2001, 97:9–13.
6. Essner R, Hsueh EC, Haigh PI, Glass EC, Huynh Y, Daghighian F: Application
of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative
detection of malignancy. J Surg Res 2001, 96:120–126.
7. Essner R, Daghighian F, Giuliano AE: Advances in FDG PET probes in
surgical oncology. Cancer J 2002, 8:100–108.
8. Higashi T, Saga T, Ishimori T, Mamede M, Ishizu K, Fujita T, Mukai T, Sato S,
Kato H, Yamaoka Y, Matsumoto K, Senda M, Konishi J: What is the most
appropriate scan timing for intraoperative detection of malignancy
using 18F-FDG-sensitive gamma probe? Preliminary phantom and
preoperative patient study. Ann Nucl Med 2004, 18:105–114.
9. Yap JT, Carney JP, Hall NC, Townsend DW: Image-guided cancer therapy
using PET/CT. Cancer J 2004, 10:221–233.
10. Barranger E, Kerrou K, Petegnief Y, David-Montefiore E, Cortez A, Daraï E:
Laparoscopic resection of occult metastasis using the combination of
FDG-positron emission tomography/computed tomography image
fusion with intraoperative probe guidance in a woman with recurrent
ovarian cancer. Gynecol Oncol 2005, 96:241–244.
11. Carrera D, Fernandez A, Estrada J, Martin-Comin J, Gamez C: Detection of
occult malignant melanoma by 18F-FDG PET-CT and gamma probe.
Rev Esp Med Nucl 2005, 24:410–413. Spanish.
12. Franc BL, Mari C, Johnson D, Leong SP: The role of a positron- and
high-energy gamma photon probe in intraoperative localization of
recurrent melanoma. Clin Nucl Med 2005, 30:787–791.
13. Kraeber-Bodéré F, Cariou B, Curtet C, Bridji B, Rousseau C, Dravet F,
Charbonnel B, Carnaille B, Le Néel JC, Mirallié E: Feasibility and benefit of
fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of
radioiodine-negative differentiated thyroid carcinoma metastases.
Surgery 2005, 138:1176–1182.
14. Gulec SA, Daghighian F, Essner R: PET-probe. Evaluation of technical
performance and clinical utility of a handheld high-energy gamma
probe in oncologic surgery. Ann Surg Oncol 2006. Epub ahead of print.
15. Meller B, Sommer K, Gerl J, von Hof K, Surowiec A, Richter E, Wollenberg B,
Baehre M: High energy probe for detecting lymph node metastases with
18F-FDG in patients with head and neck cancer. Nuklearmedizin 2006,
45:153–159.
16. Nwogu C, Fischer G, Tan D, Glinianski M, Lamonica D, Demmy T:
Radioguided detection of lymph node metastasis in non-small cell lung
cancer. Ann Thorac Surg 2006, 82:1815–1820. discussion 1820.
17. Curtet C, Carlier T, Mirallié E, Bodet-Milin C, Rousseau C, Barbet J,
Kraeber-Bodéré F: Prospective comparison of two gamma probes for
intraoperative detection of 18F-FDG: in vitro assessment and clinical
evaluation in differentiated thyroid cancer patients with iodine-negative
recurrence. Eur J Nucl Med Mol Imaging 2007, 34:1556–1562.
18. Gulec SA, Hoenie E, Hostetter R, Schwartzentruber D: PET probe-guided
surgery: applications and clinical protocol. World J Surg Oncol 2007, 5:65.
19. Gulec SA: PET probe-guided surgery. J Surg Oncol 2007, 96:353–357.
20. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW: Combined
approach of perioperative 18F-FDG PET/CT imaging and intraoperative
18F-FDG handheld gamma probe detection for tumor localization and
verification of complete tumor resection in breast cancer. World J Surg
Oncol 2007, 5:143.
21. Piert M, Burian M, Meisetschlager G, Stein HJ, Ziegler S, Nahrig J, Picchio M,
Buck A, Siewert JR, Schwaiger M: Positron detection for the intraoperative
Chapman et al. BMC Cancer 2014, 14:667 Page 12 of 13
http://www.biomedcentral.com/1471-2407/14/667localisation of cancer deposits. Eur J Nucl Med Mol Imaging 2007,
34:1534–1544.
22. Sarikaya I, Povoski SP, Al-Saif OH, Kocak E, Bloomston M, Marsh S, Cao Z,
Murrey DA, Zhang J, Hall NC, Knopp MV, Martin EW: Combined use of
preoperative 18F FDG-PET imaging and intraoperative gamma probe
detection for accurate assessment of tumor recurrence in patients with
colorectal cancer. World J Surg Oncol 2007, 5:80.
23. Sun D, Bloomston M, Hinkle G, Al-Saif OH, Hall NC, Povoski SP, Arnold MW,
Martin EW: Radioimmunoguided surgery (RIGS), PET/CT image-guided
surgery, and fluorescence image-guided surgery: past, present, and
future. J Surg Oncol 2007, 96:297–308.
24. Agrawal A, Hall NC, Ringel MD, Povoski SP, Martin EW Jr: Combined use of
perioperative TSH-stimulated 18F-FDG PET/CT imaging and gamma
probe radioguided surgery to localize and verify resection of iodine
scan-negative recurrent thyroid carcinoma. Laryngoscope 2008,
118:2190–2194.
25. Cohn DE, Hall NC, Povoski SP, Seamon LG, Farrar WB, Martin EW Jr: Novel
perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG
detection using a handheld gamma probe in recurrent ovarian cancer.
Gynecol Oncol 2008, 110:152–157.
26. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW: Bringing advanced
medical imaging into the operative arena could revolutionize the
surgical care of cancer patients. Expert Rev Med Devices 2008, 5:663–667.
27. Moffatt-Bruce SD, Povoski SP, Sharif S, Hall NC, Ross P Jr, Johnson MA,
Martin EW Jr: A novel approach to positron emission tomography in lung
cancer. Ann Thorac Surg 2008, 86:1355–1357.
28. Piert M, Carey J, Clinthorne N: Probe-guided localization of cancer
deposits using [(18)F]fluorodeoxyglucose. Q J Nucl Med Mol Imaging 2008,
52:37–49.
29. Povoski SP, Hall NC, Martin EW, Walker MJ: Multimodality approach of
perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld
gamma probe detection, and intraoperative ultrasound for tumor
localization and verification of resection of all sites of hypermetabolic
activity in a case of occult recurrent metastatic melanoma. World J Surg
Oncol 2008, 6:1.
30. Povoski SP, Sarikaya I, White WC, Marsh SG, Hall NC, Hinkle GH, Martin EW
Jr, Knopp MV: Comprehensive evaluation of occupational radiation
exposure to intraoperative and perioperative personnel from 18F-FDG
radioguided surgical procedures. Eur J Nucl Med Mol Imaging 2008,
35:2026–2034.
31. Murrey DA Jr, Bahnson EE, Hall NC, Povoski SP, Mojzisik CM, Young DC,
Sharif S, Johnson MA, Abdel-Misih S, Martin EW Jr, Knopp MV: Perioperative
(18)F-fluorodeoxyglucose-guided imaging using the becquerel as a
quantitative measure for optimizing surgical resection in patients with
advanced malignancy. Am J Surg 2009, 198:834–840.
32. Gollub MJ, Akhurst TJ, Williamson MJ, Shia J, Humm JL, Wong WD, Paty PB,
Guillem JG, Weiser MR, Temple LK, Dauer LT, Jhanwar SC, Kronman RE,
Montalvo CV, Miller AR, Larson SM, Margulis AR: Feasibility of ex vivo FDG
PET of the colon. Radiology 2009, 252:232–239.
33. Molina MA, Goodwin WJ, Moffat FL, Serafini AN, Sfakianakis GN, Avisar E:
Intra-operative use of PET probe for localization of FDG avid lesions.
Cancer Imaging 2009, 9:59–62.
34. Hall NC, Povoski SP, Murrey DA, Martin EW Jr, Knopp MV: Ex vivo specimen
FDG PET/CT imaging for oncology. Radiology 2010, 255:663–664.
35. Nalley C, Wiebeck K, Bartel TB, Bodenner D, Stack BC Jr: Intraoperative
radiation exposure with the use of (18)F-FDG-guided thyroid cancer
surgery. Otolaryngol Head Neck Surg 2010, 142:281–283.
36. de Jong JS, van Ginkel RJ, Slart RH, Lemstra CL, Paans AM, Mulder NH,
Hoekstra HJ: FDG-PET probe-guided surgery for recurrent retroperitoneal
testicular tumor recurrences. Eur J Surg Oncol 2010, 36:1092–1095.
37. Lee GO, Costouro NG, Groome T, Kashani-Sabet M, Leong SPL: The use of
intraoperative PET probe to resect metastatic melanoma. BMJ Case
Reports 2010. doi:10.1136/bcr.12.2009.2593.
38. García JR, Fraile M, Soler M, Bechini J, Ayuso JR, Lomeña F: PET/CT-guided
salvage surgery protocol. Results with ROLL technique and PET probe.
Rev Esp Med Nucl 2011, 30:217–222. Spanish.
39. Kim WW, Kim JS, Hur SM, Kim SH, Lee SK, Choi JH, Kim S, Choi JY, Lee JE,
Kim JH, Nam SJ, Yang JH, Choe JH: Radioguided surgery using an
intraoperative PET probe for tumor localization and verification of
complete resection in differentiated thyroid cancer: a pilot study.
Surgery 2011, 149:416–424.40. Manca G, Biggi E, Lorenzoni A, Boni G, Roncella M, Ghilli M, Volterrani D,
Mariani G: Simultaneous detection of breast tumor resection margins
and radioguided sentinel node biopsy using an intraoperative
electronically collimated probe with variable energy window: a case
report. Clin Nucl Med 2011, 36:e196–e198.
41. Povoski SP, Hall NC, Murrey DA Jr, Chow AZ, Gaglani JR, Bahnson EE,
Mojzisik CM, Kuhrt MP, Hitchcock CL, Knopp MV, Martin EW Jr: Multimodal
imaging and detection approach to 18F-FDG-directed surgery for
patients with known or suspected malignancies: a comprehensive
description of the specific methodology utilized in a single-institution
cumulative retrospective experience. World J Surg Oncol 2011, 9:152.
42. Francis CL, Nalley C, Fan C, Bodenner D, Stack BC Jr: 18F-fluorodeoxyglucose
and 131I radioguided surgical management of thyroid cancer.
Otolaryngol Head Neck Surg 2012, 146:26–32.
43. Bains S, Reimert M, Win AZ, Khan S, Aparici CM: A patient with psoriatic
arthritis imaged with FDG-PET/CT demonstrated an unusual imaging
pattern with muscle and fascia involvement: a case report. Nucl Med Mol
Imaging 2012, 46:138–143.
44. Vos CG, Hartemink KJ, Muller S, Oosterhuis JW, Meijer S, van den Tol MP,
Comans EF: Clinical applications of FDG-probe guided surgery. Acta Chir
Belg 2012, 112:414–418.
45. Hall NC, Povoski SP, Zhang J, Knopp MV, Martin EW Jr: Use of
intraoperative nuclear medicine imaging technology: strategy for
improved patient management. Expert Rev Med Devices 2013, 10:149–152.
46. Yasuda S, Makuuchi H, Fujii H, Nakasaki H, Mukai M, Sadahiro S, Tajima T,
Ide M, Shohtsu A, Suzuki Y: Evaluation of a surgical gamma probe for
detection of 18F-FDG. Tokai J Exp Clin Med 2000, 25:93–99.
47. Yamamoto S, Matsumoto K, Senda M: Optimum threshold setting for a
positron-sensitive probe with background rejection capability. Ann Nucl
Med 2004, 18:251–256.
48. Yamamoto S, Matsumoto K, Sakamoto S, Tarutani K, Minato K, Senda M: An
intra-operative positron probe with background rejection capability for
FDG-guided surgery. Ann Nucl Med 2005, 19:23–28.
49. Yamamoto S, Higashi T, Matsumoto K, Senda M: Development of a
positron-imaging detector with background rejection capability.
Ann Nucl Med 2006, 20:655–662.
50. Thurston MO: Development of the gamma-detecting probe for
radioimmunoguided surgery. In Radioimmunoguided Surgery (RIGS) in the
Detection and Treatment of Colorectal Cancer. 1st edition. Edited by Martin
EW. Austin: R.G. Landes Company; 1994:41–65.
51. Martin EW Jr, Thurston MO: The use of monoclonal antibodies (MAbs) and
the development of an intraoperative hand-held probe for cancer detection.
Cancer Invest 1996, 14:560–571.
52. Martin EW Jr, Thurston MO: Method for locating, differentiating, and removing
neoplasms. Publication number: US 4782840 A. Filing date September 10, 1986.
Publication date: November 8, 1988; http://www.google.com/patents/
US4782840.
53. Ramsey RC, Thurston MO: Gamma radiation detector with enhanced signal
treatment. Publication number: US 4889991 A. Filing date: September 23, 1988.
Publication date: December 26, 1989; http://www.google.com/patents/
US4889991.
54. Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW Jr:
Radioimmunoguided surgery in primary colorectal carcinoma: an
intraoperative prognostic tool and adjuvant to traditional staging. Am J
Surg 1995, 170:315–318.
55. Bertsch DJ, Burak WE Jr, Young DC, Arnold MW, Martin EW Jr:
Radioimmunoguided Surgery system improves survival for patients with
recurrent colorectal cancer. Surgery 1995, 118:634–638. discussion 638–639.
56. Bertsch DJ, Burak WE Jr, Young DC, Arnold MW, Martin EW Jr:
Radioimmunoguided surgery for colorectal cancer. Ann Surg Oncol 1996,
3:310–316.
57. Arnold MW, Hitchcock CL, Young DC, Burak WE Jr, Bertsch DJ, Martin EW Jr:
Intra-abdominal patterns of disease dissemination in colorectal cancer
identified using radioimmunoguided surgery. Dis Colon Rectum 1996,
39:509–513.
58. Barbera-Guillem E, Arnold MW, Nelson MB, Martin EW Jr: First results for
resetting the antitumor immune response by immune corrective surgery
in colon cancer. Am J Surg 1998, 176:339–343.
59. Martin EW, Chapman GJ, Subramaniam VV, Povoski SP: Intraoperative
detection of gamma emissions using K-alpha X-ray fluorescence.
Expert Rev Med Devices 2010, 7:431–434.
Chapman et al. BMC Cancer 2014, 14:667 Page 13 of 13
http://www.biomedcentral.com/1471-2407/14/66760. Currie LA: Limits for qualitative detection and quantitative determination.
Application to radiochemistry. Anal Chem 1968, 40:586–593.
61. Knoll GF: Radiation Detection and Measurement. 4th edition. New York,
New York: John Wiley & Sons, Inc; 2010.
62. Miller I, Freund JE: Probability and Statistics for Engineers. 2nd edition.
Englewood Cliffs, New Jersey: Prentice-Hall, Inc; 1977.
63. Povoski SP, Hatzaras IS, Mojzisik CM, Arnold MW, Hinkle GH, Hitchcock CL,
Young DC, Martin EW Jr: Antigen-directed cancer surgery for primary
colorectal cancer: 15-year survival analysis. Ann Surg Oncol 2012, 19:131–138.
64. Povoski SP, Hatzaras IS, Mojzisik CM, Martin EW Jr: Oncologic theranostics:
recognition of this concept in antigen-directed cancer therapy for
colorectal cancer with anti-TAG-72 monoclonal antibodies. Expert Rev
Mol Diagn 2011, 11:667–670.
65. Green DM, Swets JA: Signal Detection Theory and Psychophysics. 1st edition.
New York, New York: John Wiley & Sons, Inc; 1966.
66. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots:
a fundamental evaluation tool in clinical medicine. Clin Chem 1993,
39:561–577.
67. Akobeng AK: Understanding diagnostic tests 3: receiver operating
characteristic curves. Acta Paediatr 2007, 96:644–647.
68. Benneyan JC: Performance of number-between g-type statistical control
charts for monitoring adverse events. Health Care Manag Sci 2001, 4:319–336.
69. Phillips GW, Nagel DJ, Coffey T: A Primer on the Detection of Nuclear and
Radiological Weapons. 1st edition. Washington, DC: National Defense
University Center for Technology and National Security Policy; 2005.
70. Jendzurski J, Paulter NG: Calibration of speed enforcement down-the-road
radars. J Res Natl Inst Stand Technol 2009, 114:137–148.
doi:10.1186/1471-2407-14-667
Cite this article as: Chapman et al.: Comparison of two threshold
detection criteria methodologies for determination of probe positivity
for intraoperative in situ identification of presumed abnormal 18F-FDG-
avid tissue sites during radioguided oncologic surgery. BMC Cancer
2014 14:667.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
